Fundraising Fox
aTYR PHARMA
NASDAQ: ATYRSan Diego, US · Delaware corporation · 9 known investors
Find your way into aTYR PHARMA
Sign up to see every warm intro you have to aTYR PHARMA
- Paths you didn't know you had: your email and LinkedIn already hold routes to the aTYR PHARMA team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
Founders & leadership
Board
Investors · 9
How we know: Cardinal Partners's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$122.1M disclosed across 2 rounds · 2015–2017
▶$45.8MraisedSep 2017 · 11 investors · BiotechnologyRule 506(b)
- Jeffrey S. HatfieldDirector
- John D. MendleinExecutive Officer, Director
- John T. BlakeExecutive Officer
- Amir H. Nashat, Sc.D.Director
- Sanjay S. ShuklaExecutive Officer
- Mark GoldbergDirector
- Sanuj K. RavindranExecutive Officer
- Nancy D. KruegerExecutive Officer
- John K. ClarkeDirector
- Paul SchimmelDirector
- Srini AkkarajuDirector
- Timothy P. CoughlinDirector
- James C. BlairDirector
- Offering amount
- $45.8M
- Amount sold
- $45.8M
- Sales commissions
- $2.8M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$76.3MraisedApr 2015 · 42 investors · BiotechnologyRule 506(b)
- Amir NashatDirector
- Paul SchimmelDirector
- Akkaraju SrinivasDirector
- John D. MendleinExecutive Officer, Director
- David WeinerExecutive Officer
- Ed PenhoetDirector
- Frederic ChereauExecutive Officer
- Kathryn FalbergDirector
- James C. BlairDirector
- John K. ClarkeDirector
- Offering amount
- $76.3M
- Amount sold
- $76.3M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
4 people who came through aTYR PHARMA went on to found or lead other companies.
Related companies · 7
Companies working in the same space as aTYR PHARMA.
Frequently asked questions
- What does aTYR PHARMA do?
- aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
- Who founded aTYR PHARMA?
- aTYR PHARMA was founded by Paul Schimmel.
- Who are aTYR PHARMA's investors?
- aTYR PHARMA's investors include Cardinal Partners, EcoR1 Capital, Sofinnova Ventures, Viking Global, Domain Associates, Domain Partners, Polaris Partners, Samsara BioCapital and 1 more.
- How much funding has aTYR PHARMA raised?
- aTYR PHARMA has disclosed $122.1M raised across 2 rounds.
- Where is aTYR PHARMA headquartered?
- aTYR PHARMA is headquartered in San Diego, US.